Medicus Pharma (MDCX)
Develops clinical-stage therapies for skin cancer, urology, oncology, and women’s health.
Something off on this page? Send us feedback.
Develops SkinJect, a microneedle patch for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for oncology, urology, and women’s health. Its partnership-oriented model advances licensed or acquired programs through clinical development rather than selling medicines today.
Develops a pair of clinical-stage therapeutic platforms rather than commercializing medicines itself. SkinJect is a dissolvable microneedle patch designed to deliver doxorubicin into basal cell carcinoma lesions, while Teverelix is a long-acting GnRH antagonist under study for prostate cancer, acute urinary retention, and endometriosis.
Operates through Pennsylvania-based SkinJect and UK-based Antev, with clinical and regulatory activity across the United States, Europe, and the UAE. The model is to acquire or in-license assets, produce mid-stage clinical and regulatory data packages, then seek partnerships, regional licenses, or broader commercialization agreements. Neither platform is approved or generates product revenue; development depends on financing, external collaborators, clinical sites, licensors, and regulator decisions.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $1 |
| Jul 28, 2026 | Alliance Global Partners | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.7M · Total debt $15.3M · Total assets $19.1M · Shareholders' equity −$1.2M
- Revenue
- $0
- Operating income
- −$8.3M
- Net income
- −$8.4M
No dividends on record.
| Institutions | 4.15% | 2.62M shares | |
|---|---|---|---|
| 22 holders · as of Jun 30, 2026 | |||
| Insiders | 21.81% | 13.78M shares | |
| 12 holders · as of Sep 8, 2026 | |||
| Strategic holders | 10.40% | 6.57M shares | |
| 1 holder · as of May 21, 2025 | |||
| Other | 63.64% | 40.21M shares | |
| remainder | |||
63.18M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (63.18M in the company's Sep 22, 2026 report, 22.04M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Velocity Fund Partners, LPStrategic10 percent owner | 10.40% | 6.57M | filed May 21, 2025 |
Raza BokhariInsiderdirector, officer: Chief Executive Officer | 5.91% | 3.73M | filed Sep 8, 2026 |
Kenneth R. MelaniInsider10 percent owner | 5.26% | 3.32M | filed Dec 31, 2024 |
Ajay Raju1Insider10 percent owner | 3.17% | 2.00M | filed Dec 31, 2024 |
Interchange Capital Partners, LLCInstitution | 2.51% | 1.59M | as of Jun 30, 2026 |
- Reported at 3.70% on May 5, 2026, under the 5% line, so no further filing is required.
Insider tradesForm 4
No open-market trades in the last 12 months.
- AbbVie
GnRH therapies span Teverelix's prostate-cancer and endometriosis uses.
- Verrica Pharmaceuticals
Closest investigational non-surgical BCC treatment alternative.
- Regeneron
Approved immunotherapy for advanced BCC after Hedgehog inhibition.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medicus Pharma | $0.1681 | −0.83% | $3.8M | — | — | — | — |
| AbbVie | $263.73 | −0.43% | $467.37B | 74.5 | 17.4 | 7.3 | +10.2% |
| Verrica Pharmaceuticals | $4.51 | +1.35% | $77.1M | — | — | 2.5 | −53.9% |
| Regeneron | $799.87 | +0.15% | $82.23B | 19.7 | 13.2 | 5.3 | +16.7% |
| Median | 47.1 | 15.3 | 5.3 | +10.2% |